Pharmalive.Com Releases Annual Top 50 Biotechnology Companies Special Report With Analysis Of Corporate Strategies And Pipelines
NEWTOWN, Pa , August 12, 2010 -- Canon Data Products Group and PharmaLive.com announce the release of the annual "Top 50 Biotechnology Companies and Their Pipelines" Special Report. This compilation provides professionals working in or serving the healthcare industry with analysis of leading biotechnology companies, insight into their product pipelines, and expert review of market challenges and opportunities.
Despite economic turmoil, biotechnology companies in the U.S., Europe, Canada, and Australia had a combined net profit of $3.7 billion in 2009, a vast improvement from the $1.8 billion net loss in 2008. Biotech investment has improved as well with the Nasdaq Index currently exceeding its 2007 peak after bottoming out in 2008.
New healthcare reform laws are expected to cost major biotech companies hundreds of millions of dollars in the short term, but will even out as marketers gain access to a wider patient pool. Overall, industry leaders are pleased with the reform's provisions for biosimilars, 12-year patent exclusivity, and tax credits for innovation.
The healthcare reform bill also includes the incentives necessary to attract the major investment required for the discovery and development of novel products. To offset the competition of biosimilars, biotechnology companies are expected to fill their pipelines with next-generation, break-through biologics as they look for ways to differentiate their portfolios.
Moving forward, experts indicate that biotech firms will continue to face a challenging funding environment. Companies best poised for success are those that will increase financial and R&D efficiency and find creative models for funding and partnering.
"The modern biotechnology industry is working with newer concepts of recombinant proteins, monoclonal antibodies, gene therapy, and transgenic organisms among others with novel technologies and expansion into new therapeutic areas," says Andrew Humphreys, editor in chief of Canon Data Products Group, "which is why top biotech companies are expected to continue outpacing the overall growth of the pharmaceutical market."
This PharmaLive Special Report features a comprehensive review of the drugs in development for the top 50 biotechnology companies, which are determined based on healthcare revenue generated during 2009. The report includes:
* Expert review and highlights of the leading companies and their pipelines * Products to Watch section with data, analysis, and market overviews for some of the top companies' most-promising drugs in development
Pipeline, product, and financial analysis with easy-to-read charts detailing:
* Each products' chemical or substance composition, intended indication, clinical status, region of development, and developer/marketer * Pipeline status detailing preclinical development, Phase I, Phase II, Phase III, and awaiting approval * Region of development including the U.S., Europe, and Japan * Select 2009 and 2008 financial data such as revenue, net income, earnings per share, and R&D expenditure
This PharmaLive Special Report is available at www.PharmaLive.com/specialreports<http://www.pharmalive.com/specialreports>.
For more information, contact Sandra Baker at 215-944-9836 or Sandra.Baker@cancom.com<mailto:Sandra.Baker@cancom.com>.
About Canon Data Products Group Canon Data Products Group, a division of Canon Communications LLC, publishes PharmaLive Special Reports and Appliance Market Research Reports, which provide financial, company, and product statistical data and qualitative analysis for the global pharmaceutical, biotechnology, medical device, and appliance industries; maintains eKnowledgeBase and MDRWeb, comprehensive market intelligence tools serving the pharmaceutical, biotechnology, and medical-device sectors; and manages company-wide Site Licenses for PharmaLive.com, Med Ad News, and R&D Directions.
Posted: August 2010